Dual Action: Stenoparib is an orally available, small molecule inhibitor that uniquely targets both DNA damage repair enzymes (PARP) and key cell division and growth enzymes (Tankyrase) in tumor cells. This dual inhibitory action sets it apart from other PARP inhibitors and has the potential to provide two mechanisms of killing cancer cells. Clinical Promise: Stenoparib has demonstrated promising monotherapy activity in ovarian and pancreatic cancers during prior Phase 1 trials, showcasing its therapeutic potential. Our early Phase 2 data indicates clinical benefit in women with advanced ovarian cancer selected with our DRP^® Companion Diagnostic. Personalization: We use our clinically-validated DRP^®-Stenoparib companion diagnostic (CDx) that enables us to identify patients who will most likely benefit from this innovative therapy, paving the way for personalized cancer treatment. Tackling Resistance: Since stenoparib also inhibits Tankyrase in tumor cells, it offers new hope to patients who have developed resistance to other PARP inhibitors, addressing a critical unmet need. Combination Potential: Because of its relatively low myelotoxicity (as compared to other approved PARP inhibitors), stenoparib may be a more suitable candidate for combination treatments that hold the potential for synergistic and higher therapeutic benefit in patients. Global Perspective: Allarity holds the exclusive, global rights for stenoparib, and we have partnered with LONZA for GMP drug manufacturing in order to meet the strictest regulatory requirements worldwide.